NASDAQ:INVA Innoviva Q3 2025 Earnings Report $20.71 -0.06 (-0.28%) As of 11:24 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Innoviva EPS ResultsActual EPS$1.08Consensus EPS $0.46Beat/MissBeat by +$0.62One Year Ago EPSN/AInnoviva Revenue ResultsActual Revenue$107.80 millionExpected Revenue$91.31 millionBeat/MissBeat by +$16.50 millionYoY Revenue GrowthN/AInnoviva Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time4:00PM ETUpcoming EarningsInnoviva's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K) Innoviva Earnings HeadlinesInnoviva, Inc. (NASDAQ:INVA) Receives $36.20 Average Price Target from AnalystsAugust 1 at 2:59 AM | americanbankingnews.comInnoviva (NASDAQ:INVA) Cut to "Hold" at Wall Street ZenAugust 1 at 1:43 AM | americanbankingnews.comOnly one company survived this screenOn May 21, 2026, a federal board voted unanimously to lend one gold company roughly $3 billion. The company passed a strict four box screen: American soil, full permits, meaningful scale, and small enough that the capital transforms it. Majors like Newmont failed on scale; juniors failed on permits. It trades at about 1/50th the size of Newmont, with final loan papers expected in the second half of 2026.August 4 at 1:00 AM | Behind the Markets (Ad)Major Theravance Biopharma Investor Makes Notable Stock MoveJuly 8, 2026 | tipranks.comMajor Insider Move Rocks Theravance Biopharma SharesJuly 1, 2026 | tipranks.comIs Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?July 1, 2026 | insidermonkey.comSee More Innoviva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email. Email Address About InnovivaInnoviva (NASDAQ:INVA), incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma. The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle. Since its formation, Innoviva has supplemented its core royalty stream with additional licensing and collaboration agreements, and has pursued disciplined capital‐allocation activities to maximize dividend payments to shareholders. The firm’s contractual arrangements typically provide for tiered royalties on net sales as well as potential milestone receipts upon regulatory approvals and commercial launches. Innoviva’s royalty revenues are generated globally through collaboration partners that market, distribute and promote the underlying therapeutics both in the United States and in international territories. The company maintains a lean corporate structure, relying on third‐party manufacturing, regulatory and commercialization expertise. Innoviva is governed by an experienced board of directors and led by management professionals with backgrounds in pharmaceutical licensing, royalty financing and capital markets.View Innoviva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Dodging Deutsche Telekom: T-Mobile's Strategic WinSpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have ControlTyson Foods Offers a Meaty Opportunity for Income InvestorsStrategy's Structural Strength: Hidden in a $8 Billion IllusionMarketBeat Week in Review – 07/27- 07/31A Sweet Beat and a Wearables Rally Came With Reasons to PauseChevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Upcoming Earnings DoorDash (8/5/2026)Walt Disney (8/5/2026)MercadoLibre (8/5/2026)Occidental Petroleum (8/5/2026)Phillips 66 (8/5/2026)Allstate (8/5/2026)Brookfield Asset Management (8/5/2026)MetLife (8/5/2026)Manulife Financial (8/5/2026)Block (8/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
